Organic LETTERS

Letter

Cite This: Org. Lett. XXXX, XXX, XXX−XXX

pubs.acs.org/OrgLett

One-Pot Synthesis of Dihalogenated Ring-Fused Benzimidazolequinones from 3,6-Dimethoxy-2-(cycloamino)anilines Using Hydrogen Peroxide and Hydrohalic Acid

Martin Sweeney,[†] Lee-Ann J. Keane,[†] Michael Gurry,[†] Patrick McArdle,[†] and Fawaz Aldabbagh*[,†,‡]

[†]School of Chemistry, National University of Ireland Galway, University Road, Galway, H91 TK33, Ireland

[‡]Department of Pharmacy, School of Life Sciences, Pharmacy & Chemistry, Kingston University, Penrhyn Road, Kingston upon Thames, KT1 2EE, United Kingdom

Supporting Information

ABSTRACT: 3,6-Dimethoxy-2-(cycloamino)anilines undergo 4- or 6-electron oxidations to afford novel ring-fused halogenated benzimidazoles or benzimidazolequinones using H_2O_2/HCl or H_2O_2/HBr. Cl_2 and Br_2 are capable of the same oxidative transformation to the benzimidazolequinones. Labeling experiments indicate that water is necessary for oxidation of the *para*-dimethoxybenzenes to the corresponding quinones.



The cleanest method of generating elemental chlorine and bromine *in situ* is to mix hydrogen peroxide with excess hydrochloric and hydrobromic acid respectively, since the only byproduct is water (Scheme 1).[1,2] The intermediate is hypohalous acid (HOX), which is commonly used to disinfect water. The molecular halogen (X_2) in water is in equilibrium with an acidic (HX) solution of HOX.[3,4]

Scheme 1. Generation of X_2 from H_2O_2/HX

$$H_2O_2 + HX \longrightarrow HOX + H_2O \quad (1)$$

$$HOX + HX \rightleftharpoons X_2 + H_2O \quad (2)$$

The HOX solution has been used in the electrophilic halogenation of many aromatics.[2,5−8] On the other hand, H_2O_2 in trifluoroacetic acid (TFA) has traditionally been used to give ring-fused benzimidazoles from *o*-cyclic amine substituted anilines.[9] Recently, methanesulfonic acid (0.5−1 equiv) has replaced TFA in H_2O_2-mediated cyclizations to give alicyclic ring-fused benzimidazoles.[10] In comparison, the H_2O_2/HX system is relatively underutilized in the synthesis of heterocycles with H_2O_2/HBr used to catalyze the aziridination of alkenes with chloramine-T.[11] One-pot H_2O_2/HX-mediated oxidative cyclization of *o*-cyclic amine substituted anilines with selective dichlorination and dibromination gave a series of five- to eight-membered ring-fused benzimidazoles, generally in >80% yield (Scheme 2a).[8]

Scheme 2. H_2O_2/HX in the Preparation of Benzimidazoles and Benzimidazolequinones



Skibo and co-workers popularized aziridinyl-substituted pyrrolo[1,2-*a*]benzimidazolequinones as bioreductive antitumor alternatives to the mitomycins,[12] and other groups reported benzimidazolequinones with useful cytotoxicity,[13−21] including specificity toward hypoxic tumor cells,[18] NAD(P)H:quinone oxidoreductase 1 (NQO1)[19] and Fanconi anemia cells.[20,21]

When *para*-dimethoxybenzenes are precursors, a two-step HBr-mediated demethylation to the hydroquinone followed by $FeCl_3$-mediated oxidation is used to give the benzimidazole-

Received: October 1, 2018

DOI: 10.1021/acs.orglett.8b03135
Org. Lett. XXXX, XXX, XXX−XXX

quinone.[10,14,18,19] One-step conversion of *para*-dimethoxybenzenes to the desired quinones has been effected with AgO,[22] $Ce(NH_4)_2(NO_3)_6$ (CAN),[13,23−25] CoF_3,[26] NBS with a catalytic amount of H_2SO_4,[20,27] and $PhI(OCOCF_3)_2$ (PIFA).[28] For one-step formation of quinones, H_2O_2/HX has advantages of high atom economy[29] and low cost. The simultaneous halogenation on the aromatic or the quinone can be useful for further nucleophilic aromatic substitution[14,15,30,31] and transition-metal-catalyzed cross-couplings,[32,33] with the resultant functionalization significantly altering biological activity.[14,15,21,30,31,33] There are reports of low to moderate yields of oxidative demethylation with dihalogenation giving 5,6-dichloro- and 5,6-dibromobenzimidazolequinones using aqua regia (HNO_3/HCl (1:3))[15,16] and HBr/$NaBrO_3$, respectively.[16] However, the combination of 2-electron oxidation to the quinone with 4-electron oxidative cyclization in one pot is unknown. Herein, we utilize H_2O_2/HX to carry out oxidative cyclization, aromatic halogenation, and oxidative demethylation to give a new series of ring-fused dihalogenated benzimidazolequinones in mostly high yields (Scheme 2b). In all but one system, the protocol is tunable by adjusting the [H_2O_2] to [HX] ratio with high yields of the dihalogenated ring-fused dimethoxybenzimidazoles obtained when the [H_2O_2] is higher. Furthermore, the halogenation is selective to the activated aromatic or quinone moiety when an additional fused aromatic ring is in place.

Initially, 3,6-dimethoxy-2-(cycloamino)anilines **1a**−**1e** were treated with higher amounts of H_2O_2 (10 equiv) relative to HX (5 equiv) to give, in mostly high yields and without the need for chromatography, novel ring-fused dimethoxy-substituted benzimidazoles via a 4-electron oxidative cyclization and dihalogenation (Scheme 3). 2-(Pyrrolidin-1-yl)aniline **1a** and 2-(piperidin-1-yl)aniline **1b** were found to be consumed within 20 min in MeCN under reflux to give dichlorinated and dibrominated pyrrolo[1,2-*a*]benzimidazoles (**2a**, **3a**) and pyrido[1,2-*a*]benzimidazoles (**2b**, **3b**) in yields of 80−92%. For cyclizations of morpholine **1c**, azepane **1d**, and azocane **1e** using H_2O_2/HCl, some oxidation to the benzimidazolequinone was detected at reflux. [1,4]Oxazino[4,3-*a*]benzimidazole **2c**, azepino[1,2-*a*]benzimidazole **2d**, and azocino[1,2-*a*]-benzimidazole **2e** were selectively formed in good to high yields (67−95%) by lowering the reaction temperature (from reflux to 40 °C or rt) and increasing the reaction time (from 20 min to 2−24 h). Benzimidazolequinone formation was not detected in the HBr-mediated cyclizations of **1c**−**1e** at reflux, with **3c** obtained in 89% yield, while a 6 h reaction time afforded complete dibromination to give **3d** and **3e** in excellent yield (92% and 95%, respectively). X-ray crystal structures for the eight-membered dichlorinated and dibrominated adducts **2e** and **3e** were obtained due to similarities of respective NMR spectra.

The utility of the H_2O_2/HX-mediated system was investigated using the more challenging 2-(3,4-dihydroisoquinolin-2(1*H*)-yl)-3,6-dimethoxyaniline (THIQ substrate) **1f** with potential for halogenation on the additional aromatic ring (Scheme 3). Upon treatment of **1f** (0.07 M in MeCN) with H_2O_2 (10 equiv) and HBr (5 equiv) at reflux for 20 min, oxidative cyclization was observed at the benzylic position to afford **3f** in 73% yield. The isolation of dichlorinated analogue **2f** proved challenging under the same conditions due to the greater reactivity of the H_2O_2/HCl system. The H_2O_2/HCl system could be tuned to deliver mono- or dichlorination. At room temperature and a 4.5 h reaction time, only

Scheme 3. Synthesis of Dihalogenated Benzimidazoles Using H_2O_2/HX[a,b]



[a]Conditions: **1a**−**1f** (1.0 mmol), H_2O_2 (10 mmol), HX (5 mmol), MeCN (10 mL). [b]Isolated yields. [c]2 h, 40 °C. [d]24 h, rt. [e]5 h, 40 °C. [f]6 h. [g]MeCN (15 mL), 24 h, rt. [h]MeCN (15 mL). [i]MeCN (15 mL), 4.5 h, rt. X-ray crystal structures showing one of the two molecules in the asymmetric unit cell for **2e** and **3e** with thermal ellipsoids set at 40% probability (Figures S1 and S2), and for **4f** thermal ellipsoids set at 40% probability.

monochlorination was observed, affording **4f** in 60% yield, while reaction for 24 h afforded the dichlorinated product **2f** in 51% yield. The site of monochlorination was confirmed by X-ray crystallography on **4f**.

The room temperature reaction allowed reaction profiling by HPLC (Figure 1) with mass spectrometry detection of chlorinated aniline intermediate **1g**, suggesting that chlorination of **1f** occurs prior to oxidative cyclization. This observation may explain the selectivity of other one-pot oxidative cyclizations to benzimidazoles with aromatic halogenations,[8] which can now be assumed to be a consequence of the NH_2 of the substrate strongly directing the initial electrophilic aromatic substitution.

To carry out the one-pot overall 6-electron oxidation, to afford dihalogenated quinones, conditions which favor X_2 formation were employed (Schemes 1 and 4). H_2O_2 (50 equiv) and HCl (180 equiv) converted anilines **1a**−**1e** into dichlorinated ring-fused benzimidazolequinones **5a**−**5d** in moderate to high yields (62−80%) after 4 h in MeCN at 80 °C, while **5e** was isolated in 54% yield. For the H_2O_2/HBr-mediated transformations, the high concentrations of HBr required for quinone formation made it desirable to perform brominations under solvent-free conditions (except for **6f**, which necessitated the use of MeCN due to the lower solubility of **1f** in HBr). Dibrominated analogues **6a**−**6e** were

DOI: 10.1021/acs.orglett.8b03135
Org. Lett. XXXX, XXX, XXX−XXX



Figure 1. HPLC chromatograms as a function of time (t) for the reaction of 2-(3,4-dihydroisoquinolin-2(1*H*)-yl)-3,6-dimethoxyaniline (**1f**) with H_2O_2 (10 equiv) and HCl (5 equiv) in MeCN (15 mL) at rt. ESI HRMS (Figure S3) was used to detect 4-chloro-2-(3,4-dihydroisoquinolin-2(1*H*)-yl)-3,6-dimethoxyaniline (**1g**).

obtained in high yield (67−92%) using H_2O_2 (60 equiv) in neat HBr (30 mL) under reflux for 12 h. Ring-fused dihalogenated benzimidazolequinones (Scheme 4) were purified by flash column chromatography with the exception of dibrominated pyrrolo[1,2-*a*]benzimidazolequinone **6a**, which was isolated cleanly without purification. X-ray crystal structures of 7,8-dichloro-3,4-dihydro-1*H*-[1,4]oxazino[4,3-*a*]-benzimidazole-6,9-dione (**5c**), dichlorinated and dibrominated pyrrolo[1,2-*a*]benzimidazolequinones **5a** and **6a**, and azepino-[1,2-*a*]benzimidazolequinones **5d** and **6d** were obtained. Isolation of significant amounts of 9,10-dichloro-5,6-dihydro-benzimidazo[2,1-*a*]isoquinoline-8,11-dione (**5f**) was however not possible by treatment of THIQ **1f** with a high molar ratio of HCl relative to H_2O_2 at reflux. The reaction gave mainly inseparable products with ESI HRMS (m/z 388.9−392.9) indicative of tetrachlorination (Figure S4). This led us to employ the relatively mild conditions of H_2O_2 (10 equiv) and HCl (5 equiv) at rt, which allowed aromatic monochloride and dichloride **4f** and **2f** to be isolated in good yields after 4.5 and 24 h, respectively (Scheme 3, Figure 1), with extension to 72 h giving benzimidazolequinone **5f** in 56% isolated yield (Scheme 4, Figure S5 for the HPLC chromatograms). The structure of **5f** was confirmed by X-ray crystallography. In contrast the dibrominated analogue **6f** was isolated in 68% yield from a 7 h reflux in the presence of a large excess of HBr; over-bromination adducts were not detected. This is in line with the greater reactivity of Cl_2 relative to Br_2 in electrophilic halogenation reactions.[34]

Due to the suspected high concentration of Cl_2 or Br_2 in the one-pot 6-electron oxidative cyclizations with dihalogenation, we decided to investigate if the formation of ring-fused dihalogenated benzimidazolequinones could be effected by elemental X_2, with or without water. Chlorine gas was bubbled into a solution of anilines **1b**−**1e** in MeCN containing added H_2O (Table 1). Dichlorinated benzimidazolequinones **5b**−**5d** were isolated, but in lower yields in comparison to the H_2O_2/HCl method, although **5e** was given in a comparable yield of 58% in this 10 min reflux reaction. A comparative study, using **1c** and Cl_2, was carried out in an equivalent amount of water (10.75 mL) to the H_2O_2/HCl protocol; however, the yield of **5c** was decreased further from 54% to 47%. Thus, water is

Scheme 4. Synthesis of Dihalogenated Benzimidazolequinones Using H_2O_2/HX[a,b]



[a]Conditions: For the synthesis of dichlorides **5a**−**5e**: **1a**−**1e** (1.0 mmol), H_2O_2 (50 mmol), HCl (180 mmol), MeCN (10 mL), 4 h, 80 °C. For the synthesis of dibromides **6a**−**6f**: **1a**−**1f** (1.0 mmol), H_2O_2 (60 mmol), HBr (30 mL), 12 h, reflux. [b]Isolated yields. [c]H_2O_2 (10 mmol), HCl (5 mmol), MeCN (15 mL), 72 h, rt. [d]HBr (135 mmol), MeCN (15 mL), 7 h. X-ray crystal structures shown of **5a**, **5c**, **5d**, **5f**, **6a**, and **6d** have thermal ellipsoids set at 40% probability. Crystal structure of **6a** is one of the six molecules in the asymmetric unit cell (Figure S6).

required but not to the extent of the H_2O_2/HCl method. Moreover, yields deteriorated when the Cl_2 reaction was performed under anhydrous conditions with inseparable products given. Overchlorination of 1-methylnaphthalene was observed by Johnson et al. when Cl_2 was used under aprotic conditions.[35] Higher yields (71−90%) were achieved for the analogous one-pot transformation giving dibrominated benzimidazolequinones **6b**, **6d**, and **6e** using Br_2 and H_2O at 40 °C for 4 h, which is indicative of the greater control achieved with less reactive Br_2 (that is not susceptible to further bromination).

Finally we investigated the role of water in the quinone formation step. 7,8-Dihalo-6,9-dimethoxybenzimidazoles **2c** and **3b** were respectively treated with Cl_2 and Br_2 (both 50 equiv), and $H_2{}^{18}O$ (100 equiv) in MeCN (Scheme 5). The formation of the doubly ^{18}O-labeled dihalogenated benzimidazolequinones **7c** and **8b** was confirmed by EI-MS

DOI: 10.1021/acs.orglett.8b03135
Org. Lett. XXXX, XXX, XXX−XXX

Table 1. Synthesis of Dihalogenated Benzimidazolequinones Using Elemental Chlorine and Bromine[a,b]



1b-1e 5, 6

aniline	X	Y	*n*	yield (%)
1b	Cl	CH_2	1	**5b**, 41
1c	Cl	O	1	**5c**, 54
1c	Cl	O	1	**5c**, 47[c]
1d	Cl	CH_2	2	**5d**, 71
1e	Cl	CH_2	3	**5e**, 58
1b	Br	CH_2	1	**6b**, 71
1d	Br	CH_2	2	**6d**, 90
1e	Br	CH_2	3	**6e**, 90

[a]Conditions: For synthesis of dichlorides: **1b−1e** (1.0 mmol), Cl_2 (50 mmol), H_2O (1.8 mL), MeCN (10 mL), reflux, 10 min. For synthesis of dibromides: **1b**, **1d−1e** (1.0 mmol), Br_2 (50 mmol), H_2O (1.8 mL), MeCN (10 mL), 40 °C, 4 h. [b]Isolated yields. [c]H_2O (10.75 mL).

Scheme 5. Detecting the Role of Water in Quinone Formation with Proposed Mechanism[a]



2c, **3b** **7c**, X = Cl, Y = O; **8b**, X = Br, Y = CH_2



[a]Conditions: For dichloride **7c**: **2c** (0.07 mmol), Cl_2 (3.40 mmol), $H_2{}^{18}O$ (0.14 mL), dried MeCN (0.73 mL), reflux, 10 min. For dibromide **8b**: **3b** (0.04 mmol), Br_2 (2.05 mmol), $H_2{}^{18}O$ (0.08 mL), dried MeCN (1 mL), 40 °C, 4 h.

(Figures S7 and S8). It follows that, for both the Cl_2- and Br_2-mediated reactions, MeO-aryl bond cleavage occurred, and quinone formation did not proceed through the hydroquinone. A control experiment treating 7,8-dichloro-3,4-dihydro-1*H*-[1,4]oxazino[4,3-*a*]benzimidazole-6,9-dione **5c** with $H_2{}^{18}O$ for 4 h indicated no exchange.

In conclusion, H_2O_2/HX has led to an unprecedented one-pot 6-electron oxidative transformation to yield a new series of ring-fused dihalogenated benzimidazolequinones. The elemental halogens (X_2) generated *in situ* from H_2O_2/HX are shown to be the active species in the oxidative synthesis. When a higher molar ratio of H_2O_2 relative to HX is employed, the X_2 concentration is lower, and the 4-electron oxidative cyclization is not accompanied by oxidation to the quinone, allowing the selective formation of a new series of ring-fused dihalogenated benzimidazoles.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.orglett.8b03135.

Detailed experimental and synthetic procedures, characterization data, NMR spectra, and crystallographic data for all new compounds (PDF)

Accession Codes

CCDC 1863022−1863030 contain the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/cif, or by emailing data_request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033.

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: f.aldabbagh@kingston.ac.uk.

ORCID

Michael Gurry: 0000-0001-8161-6912

Fawaz Aldabbagh: 0000-0001-8356-5258

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

We thank the Irish Research Council (IRC) for a Government of Ireland Postgraduate Scholarship for M.S. and the College of Science, National University of Ireland Galway (NUI Galway) for a Postgraduate Scholarships for L.-A.J.K. and M.G.

■ REFERENCES

(1) Sivey, J. D.; McCullough, C. E.; Roberts, A. L. *Environ. Sci. Technol.* **2010**, *44*, 3357−3362.

(2) Ben-Daniel, R.; de Visser, S. P.; Shaik, S.; Neumann, R. *J. Am. Chem. Soc.* **2003**, *125*, 12116−12117.

(3) Eigen, M.; Kustin, K. *J. Am. Chem. Soc.* **1962**, *84*, 1355−1361.

(4) Beckwith, R. C.; Wang, T. X.; Margerum, D. W. *Inorg. Chem.* **1996**, *35*, 995−1000.

(5) Podgoršek, A.; Zupan, M.; Iskra, J. *Angew. Chem., Int. Ed.* **2009**, *48*, 8424−8450.

(6) Mukhopadhyay, S.; Ananthakrishnan, S.; Chandalia, S. B. *Org. Process Res. Dev.* **1999**, *3*, 451−454.

(7) Vyas, P. V.; Bhatt, A. K.; Ramachandraiah, G.; Bedekar, A. V. *Tetrahedron Lett.* **2003**, *44*, 4085−4088.

(8) Gurry, M.; Sweeney, M.; McArdle, P.; Aldabbagh, F. *Org. Lett.* **2015**, *17*, 2856−2859.

(9) Nair, M. D.; Adams, R. *J. Am. Chem. Soc.* **1961**, *83*, 3518−3521.

(10) Sweeney, M.; Gurry, M.; Keane, L.-A. J.; Aldabbagh, F. *Tetrahedron Lett.* **2017**, *58*, 3565−3567.

(11) Jain, S. L.; Sharma, V. B.; Sain, B. *Tetrahedron Lett.* **2004**, *45*, 8731−8732.

(12) Skibo, E. B.; Jamil, A.; Austin, B.; Hansen, D.; Ghodousi, A. *Org. Biomol. Chem.* **2010**, *8*, 1577−1587.

(13) Antonini, I.; Claudi, F.; Cristalli, G.; Franchetti, P.; Grifantini, M.; Martelli, S. *J. Med. Chem.* **1988**, *31*, 260−264.

(14) Garuti, L.; Roberti, M.; Malagoli, M.; Rossi, T.; Castelli, M. *Bioorg. Med. Chem. Lett.* **2000**, *10*, 2193−2195.

DOI: 10.1021/acs.orglett.8b03135
Org. Lett. XXXX, XXX, XXX−XXX

(15) Ryu, C.-K.; Song, E.-H.; Shim, J.-Y.; You, H.-J.; Choi, K. U.; Choi, I. H.; Lee, E. Y.; Chae, M. *Bioorg. Med. Chem. Lett.* **2003**, *13*, 17−20.
(16) Chung, K.-H.; Hong, S.-Y.; You, H.-J.; Park, R.-E.; Ryu, C.-K. *Bioorg. Med. Chem.* **2006**, *14*, 5795−5801.
(17) Gellis, A.; Kovacic, H.; Boufatah, N.; Vanelle, P. *Eur. J. Med. Chem.* **2008**, *43*, 1858−1864.
(18) Lynch, M.; Hehir, S.; Kavanagh, P.; Leech, D.; O'Shaughnessy, J.; Carty, M. P.; Aldabbagh, F. *Chem. - Eur. J.* **2007**, *13*, 3218−3226.
(19) Moriarty, E.; Carr, M.; Bonham, S.; Carty, M. P.; Aldabbagh, F. *Eur. J. Med. Chem.* **2010**, *45*, 3762−3769.
(20) O'Donovan, L.; Carty, M. P.; Aldabbagh, F. *Chem. Commun.* **2008**, *43*, 5592−5594.
(21) Fahey, K.; O'Donovan, L.; Carr, M.; Carty, M. P.; Aldabbagh, F. *Eur. J. Med. Chem.* **2010**, *45*, 1873−1879.
(22) Snyder, C. D.; Rapoport, H. *J. Am. Chem. Soc.* **1972**, *94*, 227−231.
(23) Jacob, P.; Callery, P. S.; Shulgin, A. T.; Castagnoli, N. *J. Org. Chem.* **1976**, *41*, 3627−3629.
(24) Joyce, E.; McArdle, P.; Aldabbagh, F. *Synlett* **2011**, *2011*, 1097−1100.
(25) Dao, P. D. Q.; Ho, S. L.; Cho, C. S. *ACS Omega* **2018**, *3*, 5643−5653.
(26) Tomatsu, A.; Takemura, S.; Hashimoto, K.; Nakata, M. *Synlett* **1999**, *1999*, 1474−1476.
(27) Kim, D. W.; Choi, H. Y.; Lee, K.-J.; Chi, D. Y. *Org. Lett.* **2001**, *3*, 445−447.
(28) Tohma, H.; Morioka, H.; Harayama, Y.; Hashizume, M.; Kita, Y. *Tetrahedron Lett.* **2001**, *42*, 6899−6902.
(29) Trost, B. M. *Acc. Chem. Res.* **2002**, *35*, 695−705.
(30) Ibis, C.; Tuyun, A. F.; Bahar, H.; Ayla, S. S.; Stasevych, M. V.; Musyanovych, R. Y.; Komarovska-Porokhnyavets, O.; Novikov, V. *Med. Chem. Res.* **2014**, *23*, 2140−2149.
(31) Entwistle, I. D.; Williams, P. J.; Devlin, B. R. J. Certain Benzotriazole-4,7-dione Derivatives. U.S. Patent 3,952,003, April 20, 1976.
(32) Rao, M. L. N.; Giri, S. *RSC Adv.* **2012**, *2*, 12739−12750.
(33) Louvis, A. d. R.; Silva, N. A. A.; Semaan, F. S.; da Silva, F. d. C.; Saramago, G.; de Souza, L. C. S. V.; Ferreira, B. L. A.; Castro, H. C.; Salles, J. P.; Souza, A. L. A.; Faria, R. X.; Ferreira, V. F.; Martins, D. d. L. *New J. Chem.* **2016**, *40*, 7643−7656.
(34) Voudrias, E. A.; Reinhard, M. *Environ. Sci. Technol.* **1988**, *22*, 1049−1056.
(35) Cum, G.; de la Mare, P. B. D.; Johnson, M. D. *J. Chem. Soc. C* **1967**, *0*, 1590−1598.

DOI: 10.1021/acs.orglett.8b03135
Org. Lett. XXXX, XXX, XXX−XXX